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If you want the last word on interrelationships 
between prostaglandins and cancer, try ploughing 
through this mammoth tome. It has been assembl- 
ed - with commendable speed - from material 
provided by participants at a 4-day symposium 
held at Washington in late 1981. The book con- 
tains both reviews and short reports (84 papers in 
all) in camera-ready format. There is also a decent 
index, although the cross-referencing is not very 
good: anti-inflammatory steroids appear under 4 
categories (anti-infl~mato~ drugs, cor- 
ticosteroids, ~ucoco~icoids and steroids) and each 
contains different citations. 
Taken overall, this is a monumental achieve- 
ment and the editors deserve credit for this, despite 
the fact that in the preface submitted by one of 
them (page xxxi) they have blotted their copybook 
by penning a feeble preamble containing un- 
necessary spelling errors. 
As there has been a tremendous proliferation 
(no pun intended!) of international symposia on 
prostaglan~ns (and a corresponding deluge of 
bulky proceedings) I think it is inappropriate here 
to go into the contents in much detail. The papers 
are grouped in 8 sections, the first of which pro- 
vides a general overview of prostaglandin synthetic 
pathways and pharmacology (ably presented by 
familiar contributors). Section II covers car- 
cinogenesis initiation and includes papers on the 
ability of the hydroperoxidase-containing compo- 
nent of prostaglandin synthetase to co-oxygenate 
other substrates, especially potential tumour in- 
itiators. Section III deals with the significance of 
enhanced PG synthesis following membrane lipid 
activation by tumour promoters such as the phor- 
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bol esters. The various convicting effects of pro- 
staglandins on cell replication and proliferation are 
considered in section IV. Two of the papers 
highlight the possible obligatory involvement of 
prostaglandin synthesis in the induction of in- 
terferon production and in determining its an- 
tiviral actions on target membranes. 
Sections V and VI concern the roles of pro- 
staglandins in the induction of differentiation and 
in bone resorption; in section VII are papers on 
prostaglandin effects on host-tumour interactions 
and the immune response with emphasis on. 
macrophages. The final part concerns the effects 
of manipulation of the prostaglandin system on 
tumour growth and metastasis, and includes detail- 
ed discussion by K.V. Honn of his important 
results showing that prostacyclin and nafazatrom 
(which may work by enhancing vascular pro- 
stacyclin production) are both potent anti- 
metastatic agents in animal models, possibly by in- 
terfering with tumour cell deposition dependent on 
platelet-vascular adherence. 
Clearly prostaglandins have diverse, often 
mutually opposing and possibly vital actions on 
cellular processes in tumour development. 
However, it seems unlikely that much progress will 
be made in the clinic by using either prostaglandins 
or their synthesis inhibitors (most of the results 
presented in this volume regrettably were negative) 
or in experimental situations purely by assaying for 
prostaglandin production - this gives no clues as 
to cause and effect. Nevertheless, prostaglandin in- 
volvement in cancer is a bandwagon which many 
will jump onto with relish. 
J.R.S. Hoult 
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